Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

PHASE1,PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped Due to notification from EMD Serono, for Bintrafusp alfa (M7824) regarding an observed increase in the frequently of early progression and death.

Conditions

Sarcomas
Melanomas
Germ Cell Tumors
Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas)
Pulmonary Metastases

Interventions

DEVICE: AeroEclipse II Breath Actuated Nebulizer
DRUG: Bintrafusp alfa
DRUG: Azacytidine

Sponsor

National Cancer Institute (NCI)